Patient-derived preclinical models to develop immunotherapies

Area of Science:

• Oncology
• Immunology
• Translational Medicine

Background:

• Cancer immunotherapy has transformed cancer treatment but faces challenges with non-responsive tumors.
• Understanding the tumor immune microenvironment is critical for advancing immuno-oncology.
• Novel therapeutic targets are needed to improve patient outcomes.

Purpose of the Study:

• To review patient-derived models for cancer immunotherapy research.
• To highlight the importance of studying the human tumor immune microenvironment.
• To emphasize the role of patient-derived models in advancing immuno-oncology.

Main Methods:

• Review of existing literature on patient-derived models.
• Discussion of platforms for analyzing the tumor immune microenvironment.
• Exploration of the application of these models in preclinical studies.

Main Results:

• Patient-derived models offer a platform to study cancer immunity.
• These models capture tumor immune ecosystem complexity and heterogeneity.
• They are crucial for understanding treatment mechanisms and improving clinical success.

Conclusions:

• Patient-derived models are fundamental for advancing cancer immunotherapy.
• Further research using these models will identify new therapeutic targets.
• Improved preclinical studies with patient-derived models can enhance clinical trial success.